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Abstract. The heart has been regarded as a terminally differ-
entiated organ for decades. There are numerous indicators for 
the potency of myocardial regeneration, which opens up new 
avenues for the treatment of heart disease. Cardiac stem cells 
(CSCs) have been discovered in the human heart and they play 
a vital role in myocardial regeneration. This review discusses 
the distribution, properties and proliferation of CSCs in the 
myocardium of patients with heart disease. Additionally, the 
potency of myocardial regeneration in patients with heart 
disease is discussed.
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1. Introduction
Cell therapy in cardiology is the process of transplantation of 
sufficient cells into a particular myocardial area, ensuring the 
survival and integration of the transplanted cells. Thus, cells 
for cell therapy should be multipotent and non-immunogenic, 
without oncogenic potency. Several types of stem cells have 
been discovered, including embryonic stem cells (ESCs), 
hematopoietic stem cells, mesenchymal stem cells (MSCs), 
bone marrow stem cells (BMSCs) and cardiac stem cells 
(CSCs). However, a suitable stem cell type for cell therapy in 
cardiology has not yet been identified. 
Previously, it was assumed that the loss of cardiomyocytes 
was irreversible, a hypothesis based on the generally accepted 
doctrine that cardiomyocytes are subject to terminal differen-
tiation after birth and no longer participate in the cell cycle (1). 
However, myocardial regeneration in the human heart and the 
discovery of CSCs have led to a new paradigm in cell therapy. 
Thus, this review discusses the distribution, properties 
and proliferation of CSCs in the myocardium and the potency 
of myocardial regeneration in patients with heart disease. In 
addition, the regeneration processes in the human myocardium 
are also discussed.
2. Regeneration processes in human myocardium
Previously, it was assumed that the loss of cardiomyocytes is 
irreversible and that hypertrophy of remaining cardiomyocytes 
is the only compensation for loss of cells in the heart. These 
assumptions were based on the generally accepted doctrine 
that cardiomyocytes were subject to terminal differentiation 
after birth and no longer participated in the cell cycle (1). 
However, evidence of myocardial regeneration in the human 
heart has led to a new paradigm. Consequently, the heart may 
not be a terminally differentiated organ and may have a higher 
regenerative capacity than previously assumed (Fig. 1) (2).
One study demonstrated that cardiomyocytes possess 
regenerative potential in the adult heart, as well as in animal 
hearts (3). Anversa et al first provided evidence of regenerative 
processes in the human heart following cardiac transplanta-
tion (4). The transplanted heart clearly contained immigrant 
cardiomyocyte cells with surface markers. The origin of these 
newly-formed cells are the progenitor cells of the primary 
heart, in addition to circulating progenitor cells from the 
untreated atrial remnants of the receiver (5). Further research 
revealed the existence of CSCs in the myocardium of rats, 
dogs and humans. In particular, the authors identified a cell 
population, which were the marker molecules of adult stem 
cells. However, these markers were not expressed by hemato-
poietic cells. The cell population was described as CSCs (4).
3. Characteristics of CSCs
Rodent models of myocardial infarction have revealed that 
CSCs have a potential for proliferation and myocardial regen-
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eration (7). In animal studies, these cells are differentiated into 
cardiac cell types, including cardiomyocytes, endothelial cells 
and smooth muscle cells (Fig. 2) (4). This basic hypothesis 
was strengthened by the results of other research groups, that 
described other cell populations with the characteristics of 
adult CSCs and the methods for the isolation and expansion of 
CSCs (5,7-13). Therefore, it is important to meet the prerequi-
sites for the application of this cell population in cell therapy. 
The surface markers of CSCs, including stem cell growth factor 
receptor (c-kit), a transporter protein (multidrug resistance 
protein 1; MDR-1) and a stem cell antigen (Sca-1) have been 
detected (4). Furthermore, the expression of cardiac transcrip-
tion factors, including the cardiac myosin and cytoplasmic 
proteins have also been detected in CSCs. Hematopoietic or 
bone marrow cell markers were not identified in CSCs (12). 
Further research is required to clarify whether similar cell 
populations also exist in human tissues and whether they play 
a role in pathology. Due to their local resistance, CSCs are the 
optimal choice for cell replacement therapy. Among all the cell 
populations, they are the most similar to cardiomyocytes and 
easily integrate into the myocardium. One study demonstrated 
that CSCs are able to differentiate into cardiomyocytes and 
vascular cells, which is a prerequisite for a viable myocardium. 
Furthermore, CSCs are easily isolated and duplicated in cell 
culture (5). This fact predisposes the cell population of CSCs 
for cell therapy. A limited factor may be the extremely small 
number of CSCs available. To date, it remains unclear how 
CSCs may be multiplied to produce sufficient numbers.
4. Properties and proliferation of CSCs in the myocardium 
of patients with heart disease
Studies of the myocardium of various animal species, 
including mice (9), rats (6), dogs (14) and pigs (15), revealed 
the presence of a c-kit+ CD34-CD45- cell population, which 
are similar to CSCs in the human myocardium of patients with 
heart disease (4). 
c-kit is the receptor of stem cell growth factor and a marker 
for the detection of CSCs, since c-kit+ plays an important role 
in regeneration processes of the human heart and has the 
ability to regenerate myocardial cells (16,17). Anversa et al 
demonstrated that c-kit+ cardiac cells are clonogenic multipo-
tent cells with the ability to self-renew and differentiate into at 
least three different cardiogenic cell lines, including myocytes, 
smooth muscle cells and endothelial cells (18). An animal 
model demonstrated that c-kit+ cardiac cells are able to regen-
erate functional myocardium in vivo, which was not produced 
through cell fusion (5). These cells also succeeded in the 
differentiation of three different cardiogenic cells in in vitro 
beating myocytes (9). Thus, c-kit+ cardiac cells demonstrated 
the potential for regeneration of the various components of 
the myocardium (5,10,12). In addition to c-kit, Anversa et al 
identified the population of CSCs by the two surface markers 
MDR-1 and Sca-1 (5). Urbanek et al also examined three 
markers, c-kit, Sca-1 and MDR-1, on CSCs. The authors 
demonstrated that ~60% of CSCs expressed all three markers 
and 80% of CSCs were c-kit+ (19). Thus, the population of 
CSCs that are c-kit+ is large. The absolute numbers of the total 
CSC population may be identified using c-kit as a marker. The 
potential and exact properties of these cells were investigated 
further in vivo and in vitro (20,21). 
It is known that c-kit, as a marker of hematopoietic and 
endothelial stem cells and mast cells, may also be expressed in 
the myocardium. Other studies identified that heart cells with 
surface markers of stem cells did not express the hematopoi-
etic or endothelial markers (12,13,22).
The number of c-kit+ CD34-CD45- cells has been deter-
mined. The number of c-kit+ CD34-CD45- cells in patients 
with dilated cardiomyopathy, heart failure and aortic stenosis 
was 0.19-0.21 cells/mm2 (13,23). The average number of c-kit+ 
MDR-1-Isl-1 CD45+ cells was 2.7±1.3 in human myocardium 
biopsies (17). Beltrami et al reported one stem cell per 10,000 
cardiomyocytes in rats (5) and CSCs were 0.56 per 10,000 
cardiomyocytes in the myocardium of dogs (14). Further studies 
identified a range of CSCs per 8,000-80,000 cardiomyocytes 
in mice, rats, dogs and humans (4). Although all the studies 
Figure 1. Cardiac stem cell niches in the myocardium. Following activation, 
these cells develop into cardiomyocytes and vascular structures.
Figure 2. Growth and differentiation of cardiac stem cells (CSCs).
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used c-kit as a stem cell marker, a number of studies used 
MDR-1 or Sca-1 (5,16). Moreover, not all CD34+ and CD45+ 
cells were excluded (5,17). However, CSCs are relatively rare. 
It is generally assumed that adult stem cells are rare, regardless 
of tissue (24). Thus, hematopoietic c-kit+ CD34+ stem cells, 
which were discovered ~40 years ago and therefore extremely 
well studied, were estimated at 1:10,000-1:15,000 (24).
5. Potency of myocardial regeneration in patients with 
heart disease
Studies have identified that myocardial regeneration occurs 
not only in acute pathological conditions, including following 
acute myocardial infarction, but also in chronically damaged 
hearts (13,19). It was observed that patients with heart failure 
or idiopathic dilated cardiomyopathy had significantly more 
c-kit+ CD34-CD45- cells than control subjects without cardiac 
disease (23). Several studies demonstrated the activation and 
proliferation of CSCs in damaged heart tissue (5,13,19,23). The 
occurrence of regenerative processes in pathologically altered 
myocardium suggests an increased number of CSCs, as well 
as an increased proliferative activity in the myocardium (7,10). 
It is interesting that the number of other CSC populations, 
including the number of Sca-1+ cells in the myocardium 
increases when the adult heart is subjected to a load (25). The 
increased expression of Sca-1 in cells of the hypertrophic 
myocardium leads to an increased demand for Sca-1+ cells (25).
Studies have revealed cardiac regeneration processes in 
pathologically altered myocardium; however, the regenera-
tion process is not clinically apparent. The small number of 
c-kit+ CD34-CD45- CSCs, with an average of 1.3±1.3 CSCs per 
40,000 cardiomyocytes, may not be sufficient; therefore, the 
functionally effective regeneration processes to compensate 
for serious damage in the myocardium remain uncertain.
Studies have shown that the number of CSCs in patients 
with chronic ischemic heart damage is lower than those 
with acute myocardial infarction (19). The formation of new 
cardiomyocytes is weakened by prolonged and end-stage heart 
failure decompensation (3,26). However, an increased number 
of Ki-67+ cardiomyocytes was observed in terminal heart 
failure patients who received a heart transplant. Therefore, 
regeneration processes may be secondary to myocardial 
apoptosis. Urbanek et al observed an increase in apoptotic 
processes of CSCs from 0.3 in healthy to 9.6% in chroni-
cally damaged myocardium. The authors identified that heart 
failure patients have a higher number of p53-positive senes-
cent CSCs with short telomeres. p53 and telomere shortening 
are markers of cellular aging processes (27). p53 induces 
growth arrest and cellular senescence via cyclin-dependent 
kinase (CDK)4 and CDK6, which block the retinoblastoma 
protein in its active hypophosphorylated state (28). This loss of 
functionally competent CSCs in chronic ischemic damage is 
the progressive loss of function in terminal heart failure (19). 
It is of note that c-kit+ CD34-CD45- cells could be detected 
in the myocardium of heart failure patients and healthy 
individuals (23). An increase of c-kit+ CD34-CD45- cells was 
observed in the damaged heart. However, 59% of the c-kit+ 
CD34-CD45-positive cells cells were p16INK4a-positive in the 
damaged heart, but only 14% of the c-kit+ CD34-CD45- cells 
expressed p16INK4a in the normal myocardium of control 
patients (23). The c-kit+ cells cells significantly increased in 
the myocardium of patients with heart failure (23).
An interesting aspect is the consequence of a sudden inter-
ruption of blood supply in all organs, regardless of whether 
an institution possesses proliferation capacity. The kidneys 
are known to have cells that are able to re-enter the cell cycle 
and actively proliferate (29). However, a heart attack results 
in cell death, tissue loss and scar formation in the ischemic 
region. Thus, the self-renewal potential of the heart is due to 
cell regeneration from stem cells. Slowly progressive lesions 
are compensated by this pool of cells before they enter into 
clinical appearance (13,30).
6. Origin of the c-kit+ CD34-CD45- cells and Ki-67+ 
cardiomyocytes in the myocardium of patients with heart 
disease
A significantly increased number of c-kit+ CD34-CD45- cells 
was observed in the myocardium of 19 heart failure patients 
compared with seven healthy control subjects (23). A ten-fold 
increase in the number of dividing cardiomyocytes in heart 
failure was observed in another study (19). If we define the 
dividing cardiomyocytes by the presence of the marker Ki-67, 
there is an increase of at least four times in patients with heart 
failure.
Based on the increased detection of c-kit+ CD34-CD45-
CSCs and Ki-67+ cardiomyocytes with terminal heart 
failure, the question arises as to the origin of these cells. The 
fundamental problem regarding adult stem cells is the lack of 
definition. Unlike embryonic stem cells, which are defined by 
their origin from the inner cell mass of the blastocyst, there 
is no exact definition for adult stem cells. The real origin of 
adult stem cells, independent of tissue is unknown (5). Thus, 
the origin of the increased number of c-kit+ CD34-CD45- 
cardiac cells and Ki-67+ cardiomyocytes with terminal heart 
failure was interpreted in several ways: i) activation of CSCs, 
which increases the total number and proliferative activity of 
the myocardium (5,13,14,19); ii) immigration of non-CSCs; 
iii) lack of differentiation of progenitor cells under pathological 
conditions and thus accumulation of juvenile cardiomyocytes; 
iv) dedifferentiation and expression of fetal and embryonic 
molecules of damaged adult cardiomyocytes.
In relation to ii), the detection of CD34-CD45-cells in the 
myocardium of heart failure patients may involve immigrant 
endothelial or hematopoietic progenitor cells lagging behind 
their migration into the myocardium using their endothelial 
and hematopoietic markers (31).
7. Origin of Ki-67+ cardiomyocytes and c-kit+ CD34-CD45- 
cells in patients with aortic stenosis
To analyze the cellular levels in the left ventricle of the heart, a 
large number of samples should be collected to obtain statisti-
cally reliable results. Approximately half the total number of 
c-kit+ CD34-CD45- or Ki-67+ cardiomyocytes are present in 
the left ventricle of patients with aortic stenosis. The myocar-
dium of the left ventricle is involved in the pathogenesis of 
this disease and if these cells were identified here, the regen-
eration processes would be expected, particularly since the 
rate of newly formed myocytes increases with an increase in 
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wall stress (7,10). The reason for this discrepancy may be in 
the evaluation of a given area that is exposed, particularly in 
aortic stenosis of the left ventricle, to chronic pressure load, 
resulting in the development of concentric hypertrophy (30). 
Consequently, larger and fewer cells may have been included 
in the analysis. Nevertheless, more c-kit+ Lin- and Ki-67+ 
cells were detected in samples from the outflow tract of 36 
patients with relevant aortic valve stenosis and valve replace-
ment compared with 12 control subjects who succumbed to a 
non-cardiac cause (13). An increase in Ki-67+ cardiomyocytes 
was also reported compared with c-kit+ CD34-CD45- cells. The 
growth and differentiation of stem cells into mature cardiac 
myocytes in the hypertrophied myocardium of patients with 
chronic aortic valve was associated with the fact that patients 
with aortic stenosis have good ventricular function for a 
number of years before decompensation becomes visible (32). 
It is known that patients with aortic stenosis typically remain 
asymptomatic for a long period (30).
These patients also had a good pump function [left ventric-
ular ejection fraction (LVEF), 53.2±13.2%]. This suggests 
that small, gradual restriction of ventricular function may be 
balanced in contrast to fulminant ischemia. This regeneration 
process may contribute to hemodynamic changes and remain 
stable over long periods.
8. Conclusions
The heart has long been regarded as a terminally differentiated 
organ. However, there are numerous indicators of potential 
regeneration of the myocardium. Previously, CSCs were 
discovered in the human heart and have been attributed to a 
particular role. Cell therapy in cardiology is a new method for 
the treatment of patients with heart disease. However, a suit-
able stem cell type has not yet been identified for cell therapy 
in cardiology. This review discusses the distribution, proper-
ties and proliferation of CSCs in the myocardium. The potency 
of myocardial regeneration and the regeneration processes in 
patients with heart disease were also discussed.
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